5 completed, 3 unknown, 2 recruiting, 2 terminated. 3 Not applicable, 3 Phase 2, 3 Phase 3, 2 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Completed 2, Terminated 1 |
| Phase 2 | 3 | Recruiting 1, Suspended 1, Terminated 1 |
| Phase 3 | 3 | Completed 1, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 4 | 1 | Unknown 1 |
Follow Stage II Colon Cancer: new trials by email Literature Review of Stage II Colon Cancer trials Research Report on Stage II Colon Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Postoperative Circulating Tumor DNA Monitoring in Stage I-III Driver-Mutant Colon Adenocarcinoma Longitudinal ctDNA-MRD NGS testing at scheduled postoperative time points - Colon Adenocarcinoma, Stage I Colon Cancer | Recruiting | Ruijin Hospital | 392 | 2026-08-14 | 2026-09-02 | |
| A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer OncoVAX and Surgery, Surgery - Stage II Colon Cancer | Phase 3 | Not yet recruiting | Vaccinogen Inc | 550 | 2026-08-01 | 2026-02-02 |
| Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2, Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2, Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2 - Stage I Colon Cancer, Stage II Colon Cancer | Phase 2 | Recruiting | Baylor College of Medicine | 28 | 2025-06-15 | 2025-05-25 |
| Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients 5-Fluorouracil continuous infusion FOLFOXIRI schedule, 5-Fluorouracil bolus FOLFOX schedule, 5-Fluorouracil continuous infusion FOLFOX schedule - Stage II Colon Cancer, Stage III Colon Cancer | Phase 2 | Suspended | Gruppo Oncologico del Nord-Ovest | 477 | 2023-05-17 | 2026-02-03 |
| Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab Bevacizumab, Dasatinib, Fluorouracil - Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma | Phase 1 | Completed | Anne Noonan | 9 | 2020-09-02 | 2024-12-27 |
| Adjuvant Chemotherapy in High Risk Stage II Colon Cancer FOLFOX/XELOX/Capecitabine - Stage II Colon Cancer, Adjuvant Chemotherapy | Phase 3 | Unknown | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 962 | 2020-08-01 | 2020-04-08 |
| Oxaliplatin Adjuvant Chemotherapy After Curative Resection of Primary Colon Cancer Stage II Colon Cancer, Stage III Colon Cancer | Active not recruiting | Boryung Pharmaceutical Co., Ltd | 2013 | 2020-03-25 | 2025-09-12 | |
| Real-world Retrospective Data Analysis of Adjuvant Therapy for Patients With Stage II-III Colon Cancer After Radical Surgery Stage II Colon Cancer, Stage III Colon Cancer | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 20000 | 2018-11-09 | 2021-07-15 | |
| Exercise and Colon Cancer Exercise - Stage II Colon Cancer, Stage III Colon Cancer | Not applicable | Completed | Abramson Cancer Center at Penn Medicine | 44 | 2015-12-01 | 2020-04-09 |
| Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer questionnaire administration, laboratory biomarker analysis, Standard Dietary Intervention - Stage I Colon Cancer, Stage II Colon Cancer | Not applicable | Completed | Case Comprehensive Cancer Center | 18 | 2015-02-16 | 2018-07-20 |
| A Phase II Study of Tegafur-Uracil as Maintenance Chemotherapy in Patients With Stage II of Colon Cancer tegafur-uracil - MSI-L/MSS, Stage II Colon Cancer | Phase 4 | Unknown | National Taiwan University Hospital | 300 | 2014-09-01 | 2016-09-07 |
| Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer defined green tea catechin extract, placebo, questionnaire administration - Advanced Colorectal Adenomas, Adenocarcinoma of the Colon | Phase 2 | Terminated | Mayo Clinic | 39 | 2012-06-01 | 2017-10-27 |
| Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery resveratrol, pharmacological study, laboratory biomarker analysis - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | Phase 1 | Completed | National Cancer Institute (NCI) | 20 | 2006-12-01 | 2014-09-15 |
| EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer EF5, motexafin lutetium, pharmacological study - Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix | Not applicable | Terminated | National Cancer Institute (NCI) | 30 | 2004-05-01 | 2013-01-16 |
| Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer leucovorin calcium, fluorouracil, oxaliplatin - Stage II Colon Cancer, Stage III Colon Cancer | Phase 3 | Completed | National Cancer Institute (NCI) | 2472 | 2000-02-01 | 2013-01-14 |
Colonic Neoplasms (15) · Rectal Neoplasms (4) · Bile Duct Neoplasms (2) · Colorectal Neoplasms (2) · Gallbladder Neoplasms (2) · Pancreatic Neoplasms (2) · Stomach Neoplasms (2) · Appendiceal Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Esophageal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Gastrointestinal Stromal Tumors (1) · Hereditary Sensory and Autonomic Neuropathies (1)
Colonic Diseases (15) · Digestive System Diseases (15) · Digestive System Neoplasms (15) · Gastrointestinal Diseases (15) · Gastrointestinal Neoplasms (15) · Intestinal Diseases (15) · Intestinal Neoplasms (15) · Neoplasms (15) · Neoplasms by Site (15) · Colorectal Neoplasms (13) · Rectal Diseases (5) · Bile Duct Diseases (2) · Biliary Tract Diseases (2) · Biliary Tract Neoplasms (2) · Endocrine Gland Neoplasms (2)
Fluorouracil (4) · Leucovorin (4) · Oxaliplatin (3) · Capecitabine (2) · Bevacizumab (1) · Dasatinib (1) · Disulfides (1) · Exercise (1) · Folfox protocol (1) · Immunoglobulin G (1) · Injections (1) · Irinotecan (1) · Resveratrol (1) · Surgical Procedures, Operative (1) · Tegafur (1)
National Cancer Institute (NCI) (3) · Abramson Cancer Center at Penn Medicine (1) · Anne Noonan (1) · Baylor College of Medicine (1) · Boryung Pharmaceutical Co., Ltd (1) · Case Comprehensive Cancer Center (1) · Gruppo Oncologico del Nord-Ovest (1) · Mayo Clinic (1) · National Taiwan University Hospital (1) · Ruijin Hospital (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · Vaccinogen Inc (1)
United States (9) · China (2) · Italy (1) · South Korea (1) · Taiwan (1)
Anne M Noonan, MBBChBAO, MSc (1) · Atif Iqbal, MD (1) · Been Ren Lin, Ph.D (1) · Dean Brenner (1) · Frank Sinicrope (1) · Herbert C. Hoover, MD (1) · John Kuebler (1) · Kathryn Schmitz, PhD (1) · Michael G Hanna, Jr, PhD (1) · Michelle Treasure, MD (1) · Myung Sook Hong (1) · Roberto Moretto, MD (1) · Stephen Michael Hahn (1)
PMID 17470851, PMID 17853393, PMID 20233444, PMID 21859995, PMID 21997132, PMID 24220557, PMID 27270348, PMID 31268130, PMID 32085892, PMID 33142018, PMID 33356421, PMID 38148846, PMID 38315963
P01CA087971 (1), P30CA043703 (1), P30CA046592 (1), U10CA012027 (1)